Fused Tricyclic Compounds as novel mTOR inhibitors

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof, wherein

Q is N or C(H);

R 1 is H, halo, —NR 5 R 6 , —OR 7 , —SR 8 , —CN, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclylalkyl, wherein said cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclylalkyl of R 1 is unsubstituted or substituted with one more moieties, which can be the same or different, each moiety being selected from the group consisting of halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 ;

R 2 is selected from the group consisting of heterocyclyl, spiroheterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, heteroaryl, aryl, heterocyclylalkyl, spiroheterocyclylalkyl, heterocyclenylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, arylalkyl, —O-heterocyclyl, —S-heterocyclyl, —S(O)-heterocyclyl, —S(O) 2 -heterocyclyl, —N(R 9 )-heterocyclyl, and -alkyl-N(R 9 )-heterocyclyl, wherein said heterocyclyl, spiroheterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, heteroaryl, aryl, heterocyclylalkyl, spiroheterocyclylalkyl, heterocyclenylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, arylalkyl, —O-heterocyclyl, —S-heterocyclyl, —S(O)-heterocyclyl, —S(O) 2 -heterocyclyl, —N(R 9 )-heterocyclyl, or-alkyl—N(R 9 )-heterocyclyl is unsubstituted or substituted with one to four moieties, which can be the same or different, each moiety being selected from group X;

X is alkyl, halo, —CN, —NR 5 R 6 , SR 8 , —OR 7 , —C(O)alkyl, -trihaloalkyl, -dihaloalkyl, -monohaloalkyl, —C(O) 2 alkyl, —C(O) 2 H, hydroxyalkyl, —S(O) 2 R 8 , hydroxyl, -alkyl—C(O) 2 H, -alkyl(CO)N(CH 3 )—O—CH 3 , —C(O) 2 -alkyl, -alkyl—C(O)—NH 2 , -alkyl-CN, —C(O)—NR 5 R 6 , -alkyl-C(O) 2 alkyl, —C(O)-hydroxyalkyl, —C(O)-alkyl-O-alkyl, -alkyl(CO)N(H)—S(O) 2 -cycloalkyl, -alkyl(CO)N(H)—S(O) 2 —CF 3 , -alkyl(CO)N(H)—S(O) 2 -alkyl, -alkyl-C(O)—N(alkyl) 2 , -alkyl-N(H)—S(O) 2 -alkyl, -alkyl(CO)N(H)—S(O) 2 -cycloalkyl, —C(O)—CO 2 H, —C(O)—CH(OH)—CH 3 , —C(O)CH(OH)CH 2 OH, —C(O) 2 -alkyl-aryl, —SO 2 —CF 3 , or —C(O)H, or

X is cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroarylalkyl, —NH-heterocyclyl, —C(O)-heteroaryl, wherein each of said cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroarylalkyl, —NH-heterocyclyl, —C(O)-heteroaryl of X is unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being selected from the group consisting of halogen, alkyl, cycloalkyl, —CF 3 ,

—CN, —C(O)OH, —SO 3 H, —P(O)(OH) 2 , —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 ;

R 3 is H, halogen, alkenyl, alkynyl, —CF 3 , —C(O)R 10 , aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocycloalkenyl, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, heterocyclylalkyl, heterocycloalkenylalkyl, wherein each of said aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocycloalkenyl, arylalkyl, cycloalkylalkyl, cycloalkenylalkyl, heteroarylalkyl, heterocyclylalkyl, heterocycloalkenylalkyl of R 3 is unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being selected from the group consisting of Y, halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 ;

Y is aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, or heterocycloalkenyl, wherein each of said cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, or heterocycloalkenyl of Y is unsubstituted or substituted with one more moieties, which can be the same or different, each moiety being selected from the group consisting of halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 ;

R 4 is H, halo, —NR 5 R 6 , —OR 7 , —OR 8 , —SR 9 , —CN, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclylalkyl;

each occurrence of R 5 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each occurrence of R 6 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, or R 5 and R 6 together with the nitrogen atom to which they are attached form a heterocyclyl ring;

each occurrence of R 7 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each occurrence of R 8 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each occurrence of R 9 is independently H or alkyl;

R 10 is alkyl, cycloalkyl, or aryl; and

x is an integer from 1 to 4.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is aryl or heteroaryl, wherein said aryl or heteroaryl of R 3 is unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being selected from the group consisting of Y, halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )- alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 .

3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein said aryl or heteroaryl of R 3 is substituted with one Y group.

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein said Y group is aryl or heteroaryl, wherein said aryl or heteroaryl of Y is unsubstituted or substituted with one more moieties, which can be the same or different, each moiety being selected from the group consisting of halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 .

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is pyridyl, quinolinyl, or pyrazolyl, wherein said pyridyl, quinolinyl, or pyrazolyl is unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being selected from the group consisting of Y, halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 ,—OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 .

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is heterocyclyl, cycloalkyl, cycloalkenyl, heterocyclylalkyl, cycloalkylalkyl, —O-heterocyclyl, or -alkyl-N(H)-heterocyclyl, wherein said heterocyclyl, heterocyclylalkyl, —O-heterocyclyl, or -alkyl-N(H)-heterocyclyl of R 2 is unsubstituted or substituted with one to four moieties, which can be the same or different, each moiety being selected from the group consisting of alkyl, —C(O) 2 H, —S(O) 2 CH 3 , —CH 2 C(O) 2 H, —C(O)—CH(OH)—CH 3 , and —C(O)—CH(OH)—CH 2 OH.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is H or alkyl.

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 4 is H.

9. The compound of claim 1 having the formula (Ia)

or a pharmaceutically acceptable salt thereof, wherein

Q is N or C(H);

L is —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —, —NH—CH 2 —, or —O—, or L is absent such that R 2 is bonded directly to the illustrated pyrimidine ring;

R l is H, halo, or alkyl;

R 2 is heterocyclyl, heterocyclenyl, cycloalkyl, or cycloalkenyl, wherein said heterocyclyl, heterocyclenyl, cycloalkyl, or cycloalkenyl of R 2 is unsubstituted or substituted with one to four moieties, which can be the same or different, each moiety being selected from the group X;

X is alkyl, halo, —CN, —NR 5 R 6 , SR 8 , —OR 7 , —C(O)alkyl, -trihaloalkyl, -dihaloalkyl, -monohaloalkyl, —C(O) 2 alkyl, —C(O) 2 H, hydroxyalkyl, —S(O) 2 R 8 , -alkyl-C(O) 2 H, —C(O)—CH(OH)—CH 3 , or —C(O)—CH(OH)—CH 2 OH;

R 3 is aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, heterocycloalkenyl, wherein each of said aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, or heterocycloalkenyl of R 3 is unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being selected from the group consisting of halogen, alkyl, cycloalkyl, CF 3 , CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , —S(O 2 )R 7 ; and

Y is present or absent, wherein Y, if present, is aryl or heteroaryl, wherein said aryl or heteroaryl of Y is unsubstituted or substituted with one more moieties, which can be the same or different, each moiety being selected from the group consisting of halogen, alkyl, cycloalkyl, —CF 3 , CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 19 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 ,

each occurrence of R 5 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each occurrence of R 6 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, or R 5 and R 6 together with the nitrogen atom to which they are attached form a heterocyclyl ring;

each occurrence of R 7 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each occurrence of R 8 is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

each occurrence of R 9 is independently H or alkyl;

R 19 is alkyl, cycloalkyl, or aryl; and

x is an integer from 1 to 4.

10. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein R 2 is heterocyclyl, cycloalkyl, or cycloalkenyl, wherein said heterocyclyl, cycloalkyl, or cycloalkenyl of R 2 is unsubstituted or substituted with one to four moieties, which can be the same or different, each moiety being alkyl, —C(O) 2 H, —S(O) 2 CH 3 , —CH 2 C(O) 2 H, —C(O)—CH(OH)—CH 3 , or —C(O)—CH(OH)—CH 2 OH.

11. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein R 3 is pyridyl, quinolinyl, or pyrazolyl, wherein said pyridyl, quinolinyl, or pyrazolyl is unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being selected from the group consisting of Y, halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 .

12. The compound of claim 10 or a pharmaceutically acceptable salt thereof, wherein said R 3 is pyridyl, quinolinyl, or pyrazolyl wherein said pyridyl, quinolinyl, or pyrazolyl is unsubstituted or substituted with one or more moieties which can be the same or different, each moiety being selected from the group consisting of Y, halogen, alkyl, cycloalkyl, —CF 3 , —CN, —C(O)OH, —(CH 2 ) x —C(O)OH, —OCF 3 , —OR 7 , —C(O)R 10 , —NR 5 R 6 , —C(O 2 )-alkyl, —C(O)NR 5 R 6 , —SR 8 , and —S(O 2 )R 7 .

13. A compound having one of the following formulas, or a pharmaceutically acceptable salt thereof:

14. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.